Biotech · Private company
Luye Pharma Group Ltd.
Track this companyFree. Adds Luye Pharma Group Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials101 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- DenosumabPhase 3 · Osteoporosis, PostmenopausalClinicalTrials.gov · fetched Nov 12, 2026
- INVEGA SUSTENNAPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- Invega Sustenna 156 MG in 1 ML Prefilled SyringePhase 1 · Schizo Affective DisorderClinicalTrials.gov · fetched Nov 12, 2026
- LY01005Phase 1 · Cancer of ProstateClinicalTrials.gov · fetched Nov 12, 2026
- LY03003Phase 1 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)Phase 1 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LY03005Phase 1 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- LY03010Phase 1 · Schizo Affective DisorderClinicalTrials.gov · fetched Nov 12, 2026
- LY03010 156 mg treatment group, deltoidPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- LY03010 156 mg treatment group, glutealPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- LY03010 351 mg treatment group, deltoidPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- LY03010 351 mg treatment group, glutealPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- LY03010; paliperidone palmitatePhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- LY03015 (LPM3770164 extended-release tablets)Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- Neupro 4 mg / 24 Hr. Transdermal PatchPhase 1 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Neupro 4Mg/24Hr Transdermal PatchPhase 1 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Paliperidone PalmitatePhase 1 · Schizophrenia PatientsClinicalTrials.gov · fetched Nov 12, 2026
- ZoladexPhase 1 · Cancer of ProstateClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Study of LY03015 in Healthy Chinese and Caucasian Adult SubjectsPHASE1 · COMPLETED · started Apr 15, 2026ClinicalTrials.gov NCT07671833 · fetched Nov 12, 2026
- Comparative Efficacy, Safety, PK, and Immunogenicity StudyPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 5, 2023ClinicalTrials.gov NCT05853354 · fetched Nov 12, 2026
- Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderPHASE1 · COMPLETED · started Sep 8, 2021ClinicalTrials.gov NCT05321602 · fetched Nov 12, 2026
- Relative Bioavailability of LY03010 Compared to Listed DrugPHASE1 · COMPLETED · started Jan 13, 2021ClinicalTrials.gov NCT04922593 · fetched Nov 12, 2026
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy VolunteersPHASE1 · COMPLETED · started Jun 2, 2020ClinicalTrials.gov NCT04384666 · fetched Nov 12, 2026
- Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia PatientsPHASE1 · COMPLETED · started Jan 22, 2020ClinicalTrials.gov NCT04572685 · fetched Nov 12, 2026
- A Relative Bioavailability Food Effect Study of LY03005PHASE1 · COMPLETED · started Jan 16, 2019ClinicalTrials.gov NCT03822065 · fetched Nov 12, 2026
- A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia PatientsPHASE1 · COMPLETED · started Dec 12, 2018ClinicalTrials.gov NCT03751488 · fetched Nov 12, 2026
- A Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproPHASE1 · COMPLETED · started Nov 9, 2018ClinicalTrials.gov NCT03733561 · fetched Nov 12, 2026
- A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate CancerPHASE1 · COMPLETED · started Dec 22, 2017ClinicalTrials.gov NCT03450109 · fetched Nov 12, 2026